ADIPOQ and type 2 diabetes mellitus: Adiponectin is decreased concomitantly with a higher risk of T2DM, as was suggested by Li et al. in meta-analysis studies with a total of 14 598 participants from 13 studies across different including diversified geographical and biological backgrounds in a dose–response relationship [17].